½ÃÀ庸°í¼­
»óǰÄÚµå
1477215

¸®Æ÷¼Ø ¾à¹°Àü´Þ ½ÃÀå : Á¦Ç°º°, ±â¼úº°, ÀûÀÀÁõº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº°

Liposome Drug Delivery Market, By Product, By Technology, By Indication, By End User, By Geography

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Coherent Market Insights | ÆäÀÌÁö Á¤º¸: ¿µ¹® | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¸®Æ÷¼Ø ¾à¹°Àü´Þ ½ÃÀåÀº 2024³â 54¾ï 8,220¸¸ ´Þ·¯·Î ÃßÁ¤µÇ¸ç, 2024-2031³â CAGR 8.9%·Î 2031³â¿¡´Â 99¾ï 3,560¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

º¸°í¼­ ¹üÀ§ º¸°í¼­ »ó¼¼
±âÁØ ¿¬µµ 2023³â 2024³â ½ÃÀå ±Ô¸ð 54¾ï 8,220¸¸ ´Þ·¯
½ÇÀû µ¥ÀÌÅÍ 2019-2023³â ¿¹Ãø ±â°£ 2024-2031³â
¿¹Ãø ±â°£ 2024-2031³â CAGR 8.90% 2031³â ±Ý¾× Àü¸Á 99¾ï 3,560¸¸ ´Þ·¯
±×¸². ¸®Æ÷¼Ø ¾à¹°Àü´Þ ½ÃÀå Á¡À¯À²(%), Áö¿ªº°, 2024³â
Liposome Drug Delivery Market-IMG1

¸®Æ÷¼Ø ¾à¹°Àü´ÞÀº Ç¥Àû ¾à¹°ÀÇ Àü´Þ ¹× ¹æÃâÀ» À§ÇÑ À¯¸ÁÇÑ Á¢±Ù¹ýÀÔ´Ï´Ù. ¸®Æ÷¼ØÀº ¼¼Æ÷¸·°ú À¯»çÇÑ ÁöÁú ÀÌÁßÃþÀ¸·Î ±¸¼ºµÈ ÀΰøÀûÀ¸·Î Á¦Á¶µÈ ¼ÒÆ÷·Î, ¼Ò¼ö¼º ¾à¹°°ú Ä£¼ö¼º ¾à¹°À» °¢°¢ ¼ö¼º ÄÚ¾î¿Í ÁöÁú¸· ¾È¿¡ ´ãÀ» ¼ö ÀÖ½À´Ï´Ù. À̸¦ ÅëÇØ ¸®Æ÷¼ØÀº ´Ù¾çÇÑ Ä¡·áÁ¦¸¦ Ç¥Àû ºÎÀ§¿¡ Àü´ÞÇϱâ À§ÇÑ ³ª³ë ¿î¹Ýü ¿ªÇÒÀ» ÇÏ¿© °Ç°­ÇÑ Á¶Á÷¿¡ ´ëÇÑ µ¶¼ºÀ» ÁÙÀ̸鼭 È¿´É°ú »ýü ÀÌ¿ë·üÀ» ³ôÀÏ ¼ö ÀÖ½À´Ï´Ù. ÃÖ±Ù ¸®Æ÷¼Ø Á¦Á¦ÀÇ ¹ßÀüÀ¸·Î ¾à¹° ÃæÀü ´É·Â, Ç÷¾× ¼øÈ¯ ¾ÈÁ¤¼º, ´Éµ¿Àû ¶Ç´Â ¼öµ¿Àû Ç¥ÀûÈ­ ´É·ÂÀÌ Çâ»óµÇ¾î Ç×¾ÏÁ¦, ¹é½Å, À¯ÀüÀÚ Ä¡·áÁ¦ µîÀÇ Àü´Þ È帷ΠÀ¯¸ÁÇÑ Èĺ¸¹°Áú·Î ¶°¿À¸£°í ÀÖ½À´Ï´Ù.

½ÃÀå ¿ªÇÐ:

¼¼°è ¸®Æ÷¼Ø ¾à¹°Àü´Þ ½ÃÀåÀº ¾Ï ¹× ±âŸ ¸¸¼º ÁúȯÀÇ À¯º´·ü Áõ°¡, Ç¥Àû ¾à¹°Àü´Þ ½Ã½ºÅÛ¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, ³ª³ëÀÇÇÐ ¹× ¹ÙÀÌ¿ÀÁ¦¾à ºÎ¹®ÀÇ ÁÖ¿ä ±â¾÷µéÀÇ R&D ÅõÀÚ Áõ°¡¿¡ ÈûÀÔ¾î ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. ±×·¯³ª ÀǾàǰ °³¹ß ¹× ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀΰú °ü·ÃµÈ ³ôÀº ºñ¿ëÀ¸·Î ÀÎÇØ ½ÃÀå µµÀÔÀº ¿©ÀüÈ÷ Á¦Çѵǰí ÀÖ½À´Ï´Ù. °³ÀÎ ¸ÂÃãÇü ÀÇ·á¿Í ³ª³ë±â¼ú ±â¹Ý Á¦Çü¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼­ ¸®Æ÷¼Ø ÀǾàǰ Á¦Á¶¾÷ü¿¡ Å« ºñÁî´Ï½º ±âȸ¸¦ °¡Á®´ÙÁÖ°í ÀÖ½À´Ï´Ù. Á¦¾àȸ»ç¿Í ¸®Æ÷¼Ø ±â¼ú Á¦°ø¾÷ü¿ÍÀÇ Àü·«Àû Á¦ÈÞ´Â °¨¿°, ÅëÁõ °ü¸®, ÀÚ°¡¸é¿ªÁúȯ µî ´Ù¾çÇÑ ºÐ¾ß¿¡ ´ëÇÑ Ä¡·á Àû¿ëÀ» È®´ëÇÏ´Â µ¥ µµ¿òÀÌ µÇ°í ÀÖ½À´Ï´Ù.

º» Á¶»çÀÇ ÁÖ¿ä Æ¯Â¡

  • ÀÌ º¸°í¼­´Â 2023³âÀ» ±âÁØ ¿¬µµ·Î ÇÏ¿© 2024³âºÎÅÍ 2031³â±îÁö ¿¹Ãø ±â°£(2024-2031³â)ÀÇ ½ÃÀå ±Ô¸ð(100¸¸ ´Þ·¯)¿Í ¿¬Æò±Õ ¼ºÀå·ü(CAGR)À» ÅëÇØ ¼¼°è ¸®Æ÷¼Ø ¾à¹°Àü´Þ ½ÃÀåÀ» »ó¼¼È÷ ºÐ¼®ÇÕ´Ï´Ù.
  • ¶ÇÇÑ ´Ù¾çÇÑ ºÎ¹®¿¡ °ÉÄ£ ÀáÀçÀû ¼öÀÍ ¼ºÀå ±âȸ¸¦ ¹àÈ÷°í, ÀÌ ½ÃÀå¿¡ ´ëÇÑ ¸Å·ÂÀûÀÎ ÅõÀÚ Á¦¾È ¸ÅÆ®¸¯½º¸¦ ¼³¸íÇÕ´Ï´Ù.
  • ¶ÇÇÑ ½ÃÀå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ±âȸ, ½ÅÁ¦Ç° Ãâ½Ã ¹× ½ÂÀÎ, ½ÃÀå µ¿Çâ, Áö¿ªº° Àü¸Á, ÁÖ¿ä ±â¾÷ÀÌ Ã¤ÅÃÇÑ °æÀï Àü·« µî¿¡ ´ëÇÑ Áß¿äÇÑ ÀλçÀÌÆ®µµ Á¦°øÇÕ´Ï´Ù.
  • ȸ»ç ÇÏÀ̶óÀÌÆ®, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÁÖ¿ä ÇÏÀ̶óÀÌÆ®, ¼º°ú ¹× Àü·«°ú °°Àº ¸Å°³ º¯¼ö¸¦ ±â¹ÝÀ¸·Î ¼¼°è ¸®Æ÷¼Ø ¾à¹°Àü´Þ ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷À» ÇÁ·ÎÆÄÀϸµÇÕ´Ï´Ù.
  • ÀÌ º¸°í¼­ÀÇ ÀλçÀÌÆ®¸¦ ÅëÇØ ¸¶ÄÉÆÃ ´ã´çÀÚ¿Í ±â¾÷ °æ¿µÁøÀº ÇâÈÄ Á¦Ç° Ãâ½Ã, À¯ÇüÈ­, ½ÃÀå È®´ë ¹× ¸¶ÄÉÆÃ Àü¼ú¿¡ ´ëÇÑ Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù.
  • ¼¼°è ¸®Æ÷¼Ø ¾à¹°Àü´Þ ½ÃÀåÀº ÅõÀÚÀÚ, °ø±Þ¾÷ü, Á¦Ç° Á¦Á¶¾÷ü, À¯Åë¾÷ü, ½Å±Ô ÁøÀÔÀÚ, À繫 ºÐ¼®°¡ µî ¾÷°èÀÇ ´Ù¾çÇÑ ÀÌÇØ°ü°èÀÚ¸¦ ´ë»óÀ¸·Î ÇÕ´Ï´Ù.
  • ÀÌÇØ°ü°èÀÚµéÀº ¼¼°è ¸®Æ÷¼Ø ¾à¹°Àü´Þ ½ÃÀå ºÐ¼®¿¡ »ç¿ëµÇ´Â ´Ù¾çÇÑ Àü·« ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ÀÇ»ç°áÁ¤À» ¿ëÀÌÇÏ°Ô ÇÒ ¼ö ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¸ñÀû°ú °¡Á¤

  • Á¶»ç ¸ñÀû
  • °¡Á¤
  • ¾à¾î

Á¦2Àå ½ÃÀå Àü¸Á

  • º¸°í¼­ ¼³¸í
    • ½ÃÀå Á¤ÀÇ¿Í ¹üÀ§
  • ÁÖ¿ä ¿ä¾à
  • ÀϰüÇü ±âȸ ¸Ê(COM)

Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦, µ¿Ç⠺м®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
    • ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ½ÃÀå ±âȸ
  • ¿µÇ⠺м®
  • ½ÃÀå µ¿Çâ
  • Àμö¿Í Á¦ÈÞ ½Ã³ª¸®¿À
  • ±ÔÁ¦ ½Ã³ª¸®¿À
  • Á¦Ç° ¹ß¸Å/½ÂÀÎ
  • ÀÚ±Ý Á¶´Þ°ú ÅõÀÚ
  • PEST ºÐ¼®
  • Porters ºÐ¼®

Á¦4Àå ¼¼°èÀÇ ¸®Æ÷¼Ø ¾à¹°Àü´Þ ½ÃÀå - Äڷγª¹ÙÀÌ·¯½º(COVID-19) ÆÒµ¥¹ÍÀÇ ¿µÇâ

  • ÀüüÀûÀÎ ¿µÇâ
  • Á¤ºÎ ÀÌ´Ï¼ÅÆ¼ºê
  • COVID-19¿¡ ÀÇÇÑ ½ÃÀå¿¡ ´ëÇÑ ¿µÇâ

Á¦5Àå ¼¼°èÀÇ ¸®Æ÷¼Ø ¾à¹°Àü´Þ ½ÃÀå, Á¦Ç°º°, 2019-2031³â,(100¸¸ ´Þ·¯)

  • ¼Ò°³
  • ¸®Æ÷¼Ø ÆÄŬ¸®Å¹¼¿
  • ¸®Æ÷¼Ø µ¶¼Ò·çºñ½Å
  • ¸®Æ÷¼Ø ¾ÏÆ÷Å׸®½Å B
  • ÄÚ³»½Ã°æ
  • ±âŸ

Á¦6Àå ¼¼°èÀÇ ¸®Æ÷¼Ø ¾à¹°Àü´Þ ½ÃÀå, ±â¼úº°, 2019-2031³â,(100¸¸ ´Þ·¯)

  • ¼Ò°³
  • ½ºÅÚ½º ¸®Æ÷¼Ø ±â¼ú
  • ºñPEGÈ­ ¸®Æ÷¼Ø ±â¼ú
  • â°í Æû ¸®Æ÷¼Ø ±â¼ú

Á¦7Àå ¼¼°èÀÇ ¸®Æ÷¼Ø ¾à¹°Àü´Þ ½ÃÀå, ÀûÀÀÁõº°, 2019-2031³â,(100¸¸ ´Þ·¯)

  • ¼Ò°³
  • Áø±Õ¼º Áúȯ
  • ÅëÁõ °ü¸®
  • ¾Ï Ä¡·á
  • ±âŸ

Á¦8Àå ¼¼°èÀÇ ¸®Æ÷¼Ø ¾à¹°Àü´Þ ½ÃÀå, ÃÖÁ¾»ç¿ëÀÚº°, 2019-2031³â,(100¸¸ ´Þ·¯)

  • ¼Ò°³
  • º´¿ø
  • Ŭ¸®´Ð
  • Á¶»ç½Ç
  • ±âŸ

Á¦9Àå ¼¼°èÀÇ ¸®Æ÷¼Ø ¾à¹°Àü´Þ ½ÃÀå, Áö¿ªº°, 2019-2031³â,(100¸¸ ´Þ·¯)

  • ¼Ò°³
  • ºÏ¹Ì
  • ¹Ì±¹
  • ij³ª´Ù
  • ¶óƾ¾Æ¸Þ¸®Ä«
  • ºê¶óÁú
  • ¸ß½ÃÄÚ
  • ¾Æ¸£ÇîÆ¼³ª
  • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • À¯·´
  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø, Àü³âºñ ¼ºÀå·ü(Á¦Ç°º°, 100¸¸ ´Þ·¯)
  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø, Àü³âºñ ¼ºÀå·ü(±â¼úº°, 100¸¸ ´Þ·¯)
  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø, Àü³âºñ ¼ºÀå·ü(ÀûÀÀÁõº°, 100¸¸ ´Þ·¯)
  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø, ÃÖÁ¾»ç¿ëÀÚº° Àü³âºñ ¼ºÀå·ü(100¸¸ ´Þ·¯)
  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø, Àü³âºñ ¼ºÀå·ü(±¹°¡º°, 100¸¸ ´Þ·¯)
  • ¿µ±¹
  • µ¶ÀÏ
  • ÀÌÅ»¸®¾Æ
  • ÇÁ¶û½º
  • ½ºÆäÀÎ
  • ·¯½Ã¾Æ
  • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø, Àü³âºñ ¼ºÀå·ü(Á¦Ç°º°, 100¸¸ ´Þ·¯)
  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø, Àü³âºñ ¼ºÀå·ü(±â¼úº°, 100¸¸ ´Þ·¯)
  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø, Àü³âºñ ¼ºÀå·ü(ÀûÀÀÁõº°, 100¸¸ ´Þ·¯)
  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø, ÃÖÁ¾»ç¿ëÀÚº° Àü³âºñ ¼ºÀå·ü(100¸¸ ´Þ·¯)
  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø, Àü³âºñ ¼ºÀå·ü(±¹°¡º°, 100¸¸ ´Þ·¯)
  • Áß±¹
  • Àεµ
  • ÀϺ»
  • ASEAN ±¹°¡
  • È£ÁÖ
  • Çѱ¹
  • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • Áßµ¿
  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø, Àü³âºñ ¼ºÀå·ü(Á¦Ç°º°, 100¸¸ ´Þ·¯)
  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø, Àü³âºñ ¼ºÀå·ü(±â¼úº°, 100¸¸ ´Þ·¯)
  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø, Àü³âºñ ¼ºÀå·ü(ÀûÀÀÁõº°, 100¸¸ ´Þ·¯)
  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø, ÃÖÁ¾»ç¿ëÀÚº° Àü³âºñ ¼ºÀå·ü(100¸¸ ´Þ·¯)
  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø, Àü³âºñ ¼ºÀå·ü(±¹°¡º°, 100¸¸ ´Þ·¯)
  • °ÉÇÁÇù·ÂȸÀÇ
  • À̽º¶ó¿¤
  • ±âŸ Áßµ¿
  • ¾ÆÇÁ¸®Ä«
  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø, Àü³âºñ ¼ºÀå·ü(Á¦Ç°º°, 100¸¸ ´Þ·¯)
  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø, Àü³âºñ ¼ºÀå·ü(±â¼úº°, 100¸¸ ´Þ·¯)
  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø, Àü³âºñ ¼ºÀå·ü(ÀûÀÀÁõº°, 100¸¸ ´Þ·¯)
  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø, ÃÖÁ¾»ç¿ëÀÚº° Àü³âºñ ¼ºÀå·ü(100¸¸ ´Þ·¯)
  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø, Àü³âºñ ¼ºÀå·ü(±¹°¡/Áö¿ªº°, 100¸¸ ´Þ·¯)
  • ºÏ¾ÆÇÁ¸®Ä«
  • Áß¾Ó¾ÆÇÁ¸®Ä«
  • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹

Á¦10Àå °æÀï »óȲ

  • ±â¾÷ °³¿ä
  • Gilead Sciences, Inc.
  • Luye Pharma Group
  • Ipsen Biopharmaceuticals, Inc.
  • Pacira Pharmaceuticals, Inc.
  • Acuitas Therapeutics
  • LIPOSOMA B.V.
  • Takeda Pharmaceutical Company Limited
  • Taiwan Liposome Company, Ltd.
  • Endo International
  • Jazz Pharmaceuticals plc

Á¦11Àå ¾Ö³Î¸®½ºÆ®ÀÇ °ßÇØ

  • À¶¼º°ú ¼èÅð
  • ÀϰüÇü ±âȸ ¸Ê

Á¦12Àå Âü°í¹®Çå°ú Á¶»ç ¹æ¹ý

  • Âü°í¹®Çå
  • Á¶»ç ¹æ¹ý
ksm 24.05.17

The liposome drug delivery market is estimated to be valued at USD 5,482.2 Mn in 2024 and is expected to reach USD 9,935.6 Mn by 2031, exhibiting a compound annual growth rate (CAGR) of 8.9% from 2024 to 2031.

Report Coverage Report Details
Base Year: 2023 Market Size in 2024: US$ 5,482.2 Mn
Historical Data for: 2019 To 2023 Forecast Period: 2024 To 2031
Forecast Period 2024 to 2031 CAGR: 8.90% 2031 Value Projection: US$ 9,935.6 Mn
Figure. Liposome Drug Delivery Market Share (%), By Region 2024
Liposome Drug Delivery Market - IMG1

Liposome drug delivery is a promising approach for targeted drug delivery and release. Liposomes are artificially prepared vesicles made up of lipid bilayers similar to cell membranes that can encapsulate both hydrophobic and hydrophilic drugs within their aqueous core and lipid membranes respectively. This enables liposomes to serve as nanocarriers for the delivery of various therapeutic agents to target sites, enhancing their efficacy and bioavailability while reducing toxicity to healthy tissues. Recent advancements in liposomal formulations have improved drug loading capacity, stability in blood circulation as well as active or passive targeting capabilities, making them potential candidates for delivery of anti-cancer drugs, vaccines, gene therapies, and others.

Market Dynamics:

The global liposome drug delivery market is driven by the rising prevalence of cancer and other chronic diseases, increasing demand for targeted drug delivery systems, and growing R&D investments from key players in the nanomedicine and biopharma sectors. However, high costs associated with drug development and regulatory approvals continue to restrain broader market adoption. Growing interest in personalized medicine and nanotechnology-based formulations present significant opportunities for liposome drugs manufacturers. Strategic collaborations between drug makers and liposome technology providers are helping expand therapeutic applications into areas such as infectious diseases, pain management, and autoimmune disorders.

Key Features of the Study:

  • This report provides an in-depth analysis of the global liposome drug delivery market, and provides market size (USD Mn) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year
  • It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global liposome drug delivery market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Gilead Sciences, Inc., Luye Pharma Group, Ipsen Biopharmaceuticals, Inc., Pacira Pharmaceuticals, Inc., Acuitas Therapeutics, LIPOSOMA B.V., Takeda Pharmaceutical Company Limited, Taiwan Liposome Company, Ltd., Endo International, and Jazz Pharmaceuticals plc
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global liposome drug delivery market caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global liposome drug delivery market

Detailed Segmentation-

  • Product:
    • Liposomal Paclitaxel
    • Liposomal Doxorubicin
    • Liposomal Amphotericin B
    • Others
  • Technology:
    • Stealth Liposome Technology
    • Non-PEGylated Liposome Technology
    • DepoFoam Liposome Technology
  • Indication:
    • Fungal Diseases
    • Pain Management
    • Cancer Therapeutics
    • Others
  • End User:
    • Hospitals
    • Clinics
    • Research Laboratories
    • Others
  • Region:
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East
    • Africa
  • Company Profiles:
    • Gilead Sciences, Inc.
    • Luye Pharma Group
    • Ipsen Biopharmaceuticals, Inc.
    • Pacira Pharmaceuticals, Inc.
    • Acuitas Therapeutics
    • LIPOSOMA B.V.
    • Takeda Pharmaceutical Company Limited
    • Taiwan Liposome Company, Ltd.
    • Endo International
    • Jazz Pharmaceuticals plc

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Product
    • Market Snapshot, By Technology
    • Market Snapshot, By Indication
    • Market Snapshot, By End User
    • Market Snapshot, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Market Trends
  • Recent Developments
  • Acquisitions and Partnerships Scenario
  • Regulatory Scenario
  • Product Launches/Approvals
  • Funding and Investments
  • PEST Analysis
  • Porter's Analysis

4. Global Liposome Drug Delivery Market - Impact of Coronavirus (COVID-19) Pandemic

  • Overall Impact
  • Government Initiatives
  • COVID-19 impact on the market

5. Global Liposome Drug Delivery Market, By Product, 2019 - 2031, (USD Mn)

  • Overview
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2020 - 2031
    • Segment Trends
  • Liposomal Paclitaxel
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
  • Liposomal Doxorubicin
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
  • Liposomal Amphotericin B
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
  • Nasal Endoscopes
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
  • Others
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)

6. Global Liposome Drug Delivery Market, By Technology, 2019 - 2031, (USD Mn)

  • Overview
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2020 - 2031
    • Segment Trends
  • Stealth Liposome Technology
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
  • Non-PEGylated Liposome Technology
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
  • DepoFoam Liposome Technology
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)

7. Global Liposome Drug Delivery Market, By Indication, 2019 - 2031, (USD Mn)

  • Overview
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2020 - 2031
    • Segment Trends
  • Fungal Diseases
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
  • Pain Management
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
  • Cancer Therapeutics
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
  • Others
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)

8. Global Liposome Drug Delivery Market, By End User, 2019 - 2031, (USD Mn)

  • Overview
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2020 - 2031
    • Segment Trends
  • Hospitals
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
  • Clinics
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
  • Research Laboratories
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
  • Others
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)

9. Global Liposome Drug Delivery Market, By Region, 2019 - 2031, (USD Mn)

  • Introduction
    • Market Share Analysis, By Region, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, For Region, 2020-2031
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product, 2019 - 2031, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Technology, 2019 - 2031, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2019 - 2031, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Mn)
  • U.S.
  • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product, 2019 - 2031, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Technology, 2019 - 2031, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2019 - 2031, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Mn)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Technology, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Mn)
  • U.K.
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Technology, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Mn)
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Technology, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Mn)
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Technology, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019 - 2031, (USD Mn)
  • North Africa
  • Central Africa
  • South Africa

10. Competitive Landscape

  • Company Profiles
  • Gilead Sciences, Inc. *
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
  • Luye Pharma Group
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
  • Ipsen Biopharmaceuticals, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
  • Pacira Pharmaceuticals, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
  • Acuitas Therapeutics
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
  • LIPOSOMA B.V.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
  • Takeda Pharmaceutical Company Limited
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
  • Taiwan Liposome Company, Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
  • Endo International
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
  • Jazz Pharmaceuticals plc
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies

11. Analyst View

  • Wheel of Fortune
  • Analyst View
  • Coherent Opportunity Map

12. References and Research Methodology

  • References
  • Research Methodology
  • About us and Sales Contact
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦